



IFW

**MAIL STOP AMENDMENT**  
Attorney Docket No. 27493U

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Namburi et al.

Serial No. 10/617,350

Art Unit: 1614

Filed: July 11, 2003

Examiner: ANDERSON, James D.

For: **ORAL DOSAGE FORMS OF WATER INSOLUBLE DRUGS AND METHODS  
OF MAKING THE SAME**

**TRANSMITTAL LETTER**

Commissioner for Patents  
Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- (1) Transmittal Letter; and
- (2) Response to Restriction Requirement


The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account Number 14-0112.

Respectfully submitted,

**THE NATH LAW GROUP**

Date: April 27, 2007

**THE NATH LAW GROUP**  
112 S. West Street  
Alexandria, VA 22314  
Tel: (703) 548-6284  
Fax: (703) 683-8396

  
Gary M. Nath  
Registration No. 26,965  
Josh B Goldberg  
Registration No. 44,126  
Customer No. 20529



Mail Stop Amendment  
Attorney Docket No. 27493U

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Namburi et al.

Confirmation No. 2736

Serial No. 10/617,350

Art Unit: 1614

Filed: July 11, 2003

Examiner: ANDERSON, James D.

For: **ORAL DOSAGE FORMS OF WATER INSOLUBLE DRUGS AND METHODS  
OF MAKING THE SAME**

**RESPONSE TO RESTRICTION/ELECTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

This is in response to the Official Action dated March 27, 2007. The one-month shortened statutory period for response is set to expire on April 27, 2007. Accordingly, this response is timely filed within the period for reply set by the Examiner.

**SUMMARY OF RESTRICTION REQUIREMENT**

Claims 1-41 are pending in the captioned application.

In the outstanding Official Action, the Examiner has required restriction of claims 1-41 under 35 U.S.C. §121 to one of following Groups of claims:

Group I: Claims 1-27, drawn to a process of manufacturing an active agent oral dosage form (claims 1-22) and particles produced by the process (claims 23-27), classified in class 424, subclass 490.

Group II: Claims 28-38, drawn to pharmaceutically acceptable particles (claims 28-